Profound Medical Corp. (PROF): Price and Financial Metrics
GET POWR RATINGS... FREE!
PROF POWR Grades
- PROF scores best on the Stability dimension, with a Stability rank ahead of 42.85% of US stocks.
- PROF's strongest trending metric is Growth; it's been moving down over the last 179 days.
- PROF's current lowest rank is in the Quality metric (where it is better than 5.31% of US stocks).
PROF Stock Summary
- Profound Medical Corp's stock had its IPO on October 30, 2019, making it an older stock than merely 6.57% of US equities in our set.
- PROF's price/sales ratio is 37.11; that's higher than the P/S ratio of 95.24% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.07 for Profound Medical Corp; that's greater than it is for only 6.97% of US stocks.
- If you're looking for stocks that are quantitatively similar to Profound Medical Corp, a group of peers worth examining would be IMCR, NVTA, SRNE, POWI, and QLGN.
- PROF's SEC filings can be seen here. And to visit Profound Medical Corp's official web site, go to www.profoundmedical.com.
PROF Price Target
For more insight on analysts targets of PROF, see our PROF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $26.60 | Average Broker Recommendation | 1.3 (Strong Buy) |
PROF Stock Price Chart Interactive Chart >
PROF Price/Volume Stats
| Current price | $7.21 | 52-week high | $18.26 |
| Prev. close | $7.39 | 52-week low | $6.09 |
| Day low | $7.14 | Volume | 17,400 |
| Day high | $7.45 | Avg. volume | 49,975 |
| 50-day MA | $7.81 | Dividend yield | N/A |
| 200-day MA | $10.39 | Market Cap | 150.26M |
Profound Medical Corp. (PROF) Company Bio
Profound Medical Corp. operates as a medical device company. The Company develops and commercializes technology for the treatment of localized prostate cancer. Profound Medical offers its services worldwide.
Latest PROF News From Around the Web
Below are the latest news stories about Profound Medical Corp that investors may wish to consider to help them evaluate PROF as an investment opportunity.
Companies Like Profound Medical (TSE:PRN) Are In A Position To Invest In GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and... |
Profound Medical Announces Fourth Quarter and Full Year 2021 Financial ResultsTORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with Internationa |
Profound Medical to Participate in March Investor ConferencesTORONTO, March 02, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March. 42nd Annual Cowen Health Care Conference: Profound is scheduled to present virtually on Monday, March 7, 2022 at 10:30 a.m. ET.Raymond James 43rd Ann |
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners- First Agreement Signed for a TULSA-PRO® System Interfaced with a GE Scanner -TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners. Profound subsequently signed t |
Profound Medical (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseProfound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
PROF Price Returns
| 1-mo | N/A |
| 3-mo | -19.89% |
| 6-mo | -35.80% |
| 1-year | -54.94% |
| 3-year | 20.17% |
| 5-year | 4.34% |
| YTD | -35.80% |
| 2021 | -45.38% |
| 2020 | 87.76% |
| 2019 | 160.71% |
| 2018 | -35.64% |
| 2017 | N/A |
Loading social stream, please wait...